Shopping Cart 0
Cart Subtotal
USD 0

Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company's lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer, including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigative drug candidate for mitogen-activated protein kinase pathway tumors; and KO-539, a small molecule inhibitor for the treatment of acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.

Kura Oncology Inc (KURA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11

Venture Financing 12

Kura Oncology Raises USD91.69 Million in Venture Financing 12

Partnerships 13

Kura Oncology Enters into Research Agreement with University of Michigan 13

Merger 14

Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14

Licensing Agreements 15

Kura Oncology Amends Licensing Agreement with Janssen Pharma 15

Kura Oncology Amends its Licensing Agreement with University of Michigan 17

Equity Offering 18

Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18

Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19

Kura Oncology Raises USD50 Million in Public Offering of Shares 21

Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23

Kura Oncology Inc-Key Competitors 25

Kura Oncology Inc-Key Employees 26

Kura Oncology Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Financial Announcements 28

Aug 06, 2018: Kura Oncology reports second quarter 2018 financial results and provides corporate update 28

May 08, 2018: Kura Oncology Announces First Quarter 2018 Financial Results 30

Mar 12, 2018: Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results 32

Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 34

May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 35

Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 37

Corporate Communications 38

Jul 31, 2018: Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer 38

Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 39

Legal and Regulatory 40

Jun 26, 2017: Kura Oncology added to Russell 3000 index 40

Product News 41

10/28/2017: Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML 41

01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 42

Clinical Trials 43

Oct 16, 2017: Kura Oncology Announces Late-Breaking Presentation on KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference 43

Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 44

Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 45

Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 46

Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 47

Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 48

Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kura Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11

Kura Oncology Raises USD91.69 Million in Venture Financing 12

Kura Oncology Enters into Research Agreement with University of Michigan 13

Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14

Kura Oncology Amends Licensing Agreement with Janssen Pharma 15

Kura Oncology Amends its Licensing Agreement with University of Michigan 17

Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18

Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19

Kura Oncology Raises USD50 Million in Public Offering of Shares 21

Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23

Kura Oncology Inc, Key Competitors 25

Kura Oncology Inc, Key Employees 26

Kura Oncology Inc, Other Locations 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kura Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.